Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.

[1]  A. Bruzzone,et al.  Prognostic significance of α‐ and β2‐adrenoceptor gene expression in breast cancer patients , 2019, British journal of clinical pharmacology.

[2]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[3]  B. Gyawali,et al.  Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials , 2018, Breast Cancer Research and Treatment.

[4]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[5]  S. Loi,et al.  Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study , 2018 .

[6]  J. Gehl,et al.  Exercise-Induced Catecholamines Activate the Hippo Tumor Suppressor Pathway to Reduce Risks of Breast Cancer Development. , 2017, Cancer research.

[7]  J. Mackey,et al.  Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  B. Bryan,et al.  Beta-adrenergic receptors are expressed across diverse cancers , 2017, Oncoscience.

[9]  S. Copsel,et al.  A Novel Effect of β-Adrenergic Receptor on Mammary Branching Morphogenesis and its Possible Implications in Breast Cancer , 2017, Journal of Mammary Gland Biology and Neoplasia.

[10]  Mats Lambe,et al.  Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts , 2016, Breast Cancer Research.

[11]  Masashi Kato,et al.  Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma , 2016, Oncotarget.

[12]  Sara Gandini,et al.  Use of beta‐blockers, angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta‐analysis , 2016, International journal of cancer.

[13]  Joel S. Parker,et al.  Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer , 2016, Bioinform..

[14]  C. Sotiriou,et al.  Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer , 2015, BMC Medicine.

[15]  Marius Raica,et al.  The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. , 2015, Anticancer research.

[16]  H. Chen,et al.  β2-AR signaling controls trastuzumab resistance-dependent pathway , 2015, Oncogene.

[17]  Krishna R. Kalari,et al.  Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Żebrowska,et al.  Adrenergic Response to Maximum Exercise of Trained Road Cyclists , 2014, Journal of human kinetics.

[19]  R. Chlebowski.  Nutrition and physical activity influence on breast cancer incidence and outcome. , 2013, Breast.

[20]  Mark A Sussman,et al.  &bgr;-Adrenergic Regulation of Cardiac Progenitor Cell Death Versus Survival and Proliferation , 2013, Circulation research.

[21]  Stefan Michiels,et al.  Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  John Quackenbush,et al.  A three-gene model to robustly identify breast cancer molecular subtypes. , 2012, Journal of the National Cancer Institute.

[23]  K. Bennett,et al.  Beta blockers and breast cancer mortality: a population- based study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Hortobagyi,et al.  Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  I. Ellis,et al.  Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival , 2010, Oncotarget.

[26]  前田 邦彦,et al.  山形県の乳癌の病理学的特性-HER2 (human epidermal growth factor receptor 2)の発現率に関する調査- , 2010 .

[27]  Jorma Isola,et al.  Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[29]  G. Viani,et al.  Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials , 2007, BMC Cancer.

[30]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[31]  A. Chinnaiyan,et al.  Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. , 2006, Cancer research.

[32]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[33]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[34]  Peter Carmeliet,et al.  VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.

[35]  J. Isola,et al.  Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization , 2004, Clinical Cancer Research.

[36]  M. Walters,et al.  Cross-talk Between &bgr;-Adrenergic Stimulation and Estrogen Receptors: Isoproterenol Inhibits 17&bgr;-Estradiol-Induced Gene Transcription in A7r5 Cells , 2003, Journal of cardiovascular pharmacology.

[37]  G. Wallukat,et al.  The β-Adrenergic Receptors , 2002, Herz.

[38]  V. Sanders,et al.  IFN-γ Production by Th1 Cells Generated from Naive CD4+ T Cells Exposed to Norepinephrine1 , 2001, The Journal of Immunology.

[39]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[40]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[41]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[42]  Ming Yu,et al.  The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells , 2010, Breast Cancer Research and Treatment.

[43]  Malcolm W Johnson.  Molecular mechanisms of β2-adrenergic receptor function, response, and regulation , 2006 .

[44]  W. Lee,et al.  IFN-gamma production by Th1 cells generated from naive CD4+ T cells exposed to norepinephrine. , 2001, Journal of immunology.